CSL Limited

Equities

CSL

AU000000CSL8

Pharmaceuticals

Delayed Australian S.E. 11:30:12 2024-05-28 pm EDT 5-day change 1st Jan Change
279.5 AUD -0.89% Intraday chart for CSL Limited +0.49% -2.51%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
US, European nations consider vaccinating workers exposed to bird flu RE
Banks push Australia shares down; James Hardie dips to 5-month low RE
Australia shares retreat as banks, technology, healthcare stocks drag RE
Australia shares jump as US inflation data reinforces rate-cut hopes RE
Australian shares end flat as miners offset losses in banks, energy; US CPI on tap RE
Australian shares gain on fresh Fed rate-cut hopes, on track for best week in 5 RE
Australian shares retreat as miners, banks drag; CBA down on lower profit RE
Australia's CSL tests 'dynamic pricing' of donor blood amid cost surge RE
Commodity stocks lift Australian shares; RBA decision on tap RE
Australian shares rise on US rate cut hopes; RBA in focus RE
Australian shares fall as miners and banks drag; Fed in focus RE
Ars Pharmaceuticals, Inc. Enters Exclusive License and Distribution Agreement with CSL Seqirus for Commercialization of Neffy in Australia and New Zealand CI
Australian shares rise on banks, IT boost; Fed policy meet on tap RE
Australian shares tumble as miners, energy stocks fall; BHP Group tanks RE
CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® for the Treatment of IgA Nephropathy CI
Australian shares climb on banks, energy boost; March-quarter CPI in focus RE
Australian shares follow Wall Street higher, miners limit gains RE
Australian shares rebound as miners and financials jump; inflation data awaited RE
Vifor Pharma offers to rectify anti-competitive behaviour against rival RE
Miners boost Australian shares; NZ cenbank keeps rates steady RE
New Zealand shares hold gains as c.bank expectedly holds rate; Aussie shares up RE
Australian shares rise on mining and healthcare boost; US CPI data, RBNZ in focus RE
Australian shares end higher as miners surge; US CPI in focus RE
Australian shares fall as financials and healthcare stocks drag RE
Australian shares hit record high; RBA cautious on inflation RE
Chart CSL Limited
More charts
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
187.8 USD
Average target price
202.7 USD
Spread / Average Target
+7.92%
Consensus
  1. Stock Market
  2. Equities
  3. CSL Stock
  4. News CSL Limited
  5. Jarden Research Adjusts CSL’s Price Target to AU$298.57 From AU$316.16, Keeps at Overweight